Analysis of the EGFR Mutation Status in Head and Neck Squamous Cell Carcinoma before Treatment with Gefitinib

Sven Bontognali,a,b Miklos Pless,a,b,e Martin H. Brutsche,a,e Claude Fischer,a,c,f Christoph Rochlitz,a,b Martin Buess,a,b,g

aKopf-Hals-Tumor-Zentrum, bAbteilung medizinische Onkologie, cHals-Nasen-Ohren-Klinik, Universitätsspital Basel,
dTumorzentrum Kantons spitäl Winterthur, *Pneumologie Kantons spitäl St. Gallen, fORL-Klinik Kantons spitäl Graubünden, Chur,
gSt. Claraspital, Basel, Switzerland

Keywords
Gefitinib · Squamous cell carcinoma of the head and neck · EGFR · Predictive

Summary
Background: The efficacy of chemotherapy in metastatic and recurrent squamous cell carcinomas of the head and neck (HNSCC) remains unsatisfactory. Gefitinib offers a new therapeutic option with comparable results and better tolerability than chemotherapy. We conducted this study to see if mutations in the epidermal growth factor receptor (EGFR) might predict the therapeutic benefit in HNSCC patients. Patients and Methods: In a pilot trial, 8 patients with metastatic or recurrent HNSCC were treated palliatively with gefitinib (500 mg/day orally). Forceps biopsies were taken to confirm tumor recurrence and to perform an EGFR mutation analysis. Results: The EGFR status could be determined in 6 of the 8 patients. 5 patients had no EGFR gene mutation, and 1 patient showed a silent guanine-to-adenosine mutation in position 2607. Even without any relevant mutation in the EGFR, we observed partial remission in 3 of 6 patients treated with gefitinib. We also observed that an additional 4 patients had stable disease for at least 10 weeks. The median progression-free survival was 6.25 months, and the median overall survival was 7.39 months. Conclusion: In HNSCC, there are tumor responses to gefitinib without protein-altering mutations in the EGFR gene.

Schlüsselwörter
Gefitinib · Plattenehfelkarkarinom · Kopf-Hals-Tumor · EGFR · Prädiktiv

Zusammenfassung
**Introduction**

The survival rates of patients with squamous cell carcinoma of the head and neck (HNSCC) have not much improved over the last decade [1]. Curative approaches are in competition with their functional and cosmetic outcomes, which significantly influence the patient’s quality of life [2]. About half of the treated patients will relapse locally or with distant metastases. The treatment of recurrent and metastatic HNSCC is a major therapeutic challenge. The prognosis of patients with recurrent or metastatic HNSCC is generally poor, with a median survival of about 6 months [3]. Patients in good general condition and with locally recurrent disease can benefit again from either surgery or further radiotherapy [4]. For patients with metastatic or unresectable recurrent disease without the option for re-irradiation, conventional chemotherapy or targeted agents are the only treatment options.

The response rates with conventional chemotherapeutic agents generally reach 15–30% with a response duration of 3–5 months [5–7]. Several randomized trials have shown that combination chemotherapy showed a higher response rate, but this comes at the price of increased toxicity and without any significant survival advantage [8]. It has recently been shown for the first time that, in addition to conventional chemotherapy, a targeted agent against the epidermal growth factor receptor (EGFR), cetuximab, significantly improves the median overall survival (OS) by 2.5 months [9]. However, in second-line therapy, the response rates are minimal. In a multi-institutional retrospective analysis of 151 patients with progressive cancer following treatment with platinum-based therapy, the overall response rate was 2.6%, and the median time to tumor progression with best supportive care, chemotherapy or chemotherapy and radiotherapy was 45, 67, 131, and 153 days, respectively [10]. Novel therapeutic strategies are urgently needed.

The EGFR is overexpressed in up to 90% of HNSCC cases [11–13]. Malignant cells express 50–100 times more EGFR than normal keratinocytes [14]. Often, overexpression of the EGFR is associated with an increased production of EGFR ligands, which results in an autocrine stimulation of the tumor cells [15]. This autocrine signaling of EGF and EGFR may be blocked by EGFR antibodies like cetuximab or other small-molecule inhibitors of the EGFR tyrosine kinase-1 [16]. One of these small-molecule inhibitors is gefitinib, a synthetic anilinoquinazoline. Gefitinib is taken orally and acts to selectively inhibit the EGFR tyrosine kinase [17]. In vitro and in vivo preclinical studies in tumor cell lines in mice showed a dose-dependent anti-proliferative effect of gefitinib [18]. As monotherapies, the EGFR inhibitors have modest overall activity with response rates of 1–11% for gefitinib [19] and erlotinib [20]. However, compared to a conventional chemotherapy regimen with methotrexate, gefitinib showed equal survival rates but fewer side effects [7]. From the experience with non-small-cell lung cancer, it is known that the response rates to gefitinib in an unselected patient population are disappointingly small [21]. However, some patients showed a tumor response that has not been previously observed in treatment with conventional chemotherapy. In a landmark study, Lynch et al. [22] were able to demonstrate that 8 of 9 patients with gefitinib-sensitive adenocarcinomas of the lung had a somatic mutation in the tyrosine kinase domain of the EGFR while no mutations were found in gefitinib-resistant cancers. The mutations detected were either small in-frame deletions or amino acid substitutions that accumulated near the ATP binding site of the tyrosine kinase domain.

The aim of this study was to determine whether there is a correlation between the tumor response of HNSCC to treatment with gefitinib and alterations in the EGFR. If so, the possibility might exist for a more targeted approach to treat HNSCC with gefitinib and improve its therapeutic efficacy.

**Patients and Methods**

In this pilot trial at the interdisciplinary head and neck cancer center of the Basel University Hospital, 8 patients with HNSCC were enrolled. The protocol was approved by the ethical committee of Basel (EKBB 97/03). Patients with recurrent and unresectable locoregional and/or distant metastatic HNSCC with either progressive disease after at least 1 prior chemotherapy or chemoradiotherapy regimen or patients with no better treatment options were eligible for the trial. Eligibility criteria included a life expectancy > 3 months, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 2, and adequate hematologic, renal and liver function. Exclusion criteria included significant comorbidities (including coronary artery disease, symptomatic congestive heart failure, active alcohol abuse, bleeding diathesis, history of interstitial lung disease, or gastrointestinal ulcer within 12 months); concurrent use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St John’s wort; or surgery or radiotherapy within 30 days.

Treatment with gefitinib was provided free of charge by AstraZeneca as part of a compassionate use program. The planned regimen recommended that gefitinib be administered orally at a dose of 250 mg twice daily within a treatment cycle of 28 days.

Tumor assessment for response took place at the end of every 2nd cycle (i.e., 8 weeks) of therapy. In patients completing 6 cycles of therapy, the evaluation for response was performed after every 3rd cycle. Response was assessed radiographically according to the Response Evaluation Criteria in Solid Tumors (RECIST) [23] and by physical examination. Patients with at least stable disease (SD) continued treatment with gefitinib until either tumor progression or unacceptable toxicity occurred. All patients were dead at the time of analysis. Progression-free survival (PFS) and OS were estimated from the start of therapy until disease progression or date of death.

**Method of EGF Receptor Mutation Analysis**

A forceps biopsy was taken for standard diagnostic purposes, and a second forceps biopsy was obtained for the current study during the same intervention. Both biopsies were put directly into the RNA preservation solution, RNA later (Ambion®), kept for 1 h in a –20 °C freezer and then frozen and stored at –80 °C.
RNA Isolation

Total RNA was extracted using the optimized TRIZOL® reagent (Invitrogen). For this purpose, we followed the protocol of the RNeasy® Micro Kit for RNA purification, which included on-column DNase treatment to eliminate genomic DNA in the samples.

Reverse Transcription

For the reverse transcription (RT) of mRNA, 200 ng of total RNA was mixed in a volume of 7 μl with 3 mM dT25 primer. To perform the annealing, the RNA and dT25 primer were kept for 10 min at 65 °C and then immediately cooled on ice. The cDNA synthesis was carried out with the help of 1 μl (100 U) of SuperScript® reverse transcriptase MMLV (Boehringer) in 12 μl RT buffer (containing 200 mM dNTP, 10 mM dithiothreitol (DTT) and 40 U RNAsin® (Boehringer)) for 1 h at 42 °C. The cDNA was stored at −20 °C thereafter.

Polymerase Chain Reaction

To perform the polymerase chain reaction (PCR) for the amplification of exons 19–21 of the EGFR gene, the 18-mer primer EGF-1 (GeneID: 1956, Consensus CDS: CCDS5514.1) forward (GCTTGTGGAGCCTCTTAC) and a 19-mer reverse primer (GGTGTTATTAGATTCTGTG) were used. The PCR was carried out in a volume of 50 μl, which included the buffer and the enzyme from the Advantage Klen Taq KIT® (Clontech). The reaction was carried out with 1 mM of primers, 10 mM dNTP and 5 μl RT product as the template. For amplification, the following cycling protocol was used: 15 s at 94 °C, 30 s at 63 °C, and 30 s at 72 °C, for 35 cycles.

Sequencing of PCR Products

The sequencing of the PCR fragments was carried out after the cycle sequencing protocol and subsequent capillary electrophoresis according to the standard protocol of Microsynth AG (Balgach, Switzerland). When sequencing, the 21-mer primer GGAGCCTCTTACACCCAGTGG was used. The sequences were compared with the wild-type EGFR gene sequence using the Blast program.

Results

Patient Characteristics

HNSCC was confirmed in all patients by either cytology or histology. The initial diagnosis was established by the Institute of Pathology within the University of Basel between 1999 and 2003. The patient characteristics are given in table 1. Overall, the patients represented a population of mostly heavily pretreated patients who had either recurrent or metastatic disease.

The Gefitinib Therapy

Patients received a total of 53 cycles of treatment (median 7 cycles, range 1–12 cycles). 4 patients were treated with 500 mg of gefitinib daily. In 2 of these patients, the dose had to be reduced to 250 mg/day due to side effects during the course of the disease. In the other 2 patients, the full dose was used until discontinuation due to tumor progression occurred on days 78 and 258, respectively. The 4 other patients were treated with 250 mg of gefitinib from the beginning of the study; a dose reduction was never necessary. The average duration of gefitinib therapy without a break was 190 days (range 43–333 days). On average, patients were treated with 500 mg/day of gefitinib for 73 days (range 0–258 days) and with 250 mg/day of gefitinib for 116 days (range 0–268 days). The average cumulative total dose was 65.9 g (range 10.7–129 g). The average cumulative total dose obtained was 69% of the expected total dose, which was equivalent to a dose reduction of 31%. Reasons for discontinuation included tumor progression (2/8), death (4/8), and side effects (2/8). 6 patients received no further treatment after gefitinib, 1 patient received chemotherapy with cisplatin and 1 patient received chemotherapy with docetaxel, radiotherapy and bisphosphonate treatment after stopping gefitinib.

Side Effects of Gefitinib Therapy

The most common side effects of gefitinib therapy were varying degrees of skin rash and diarrhea. 6 patients had skin rashes greater than grade 2, and 2 patients had diarrhea greater than grade 2. Because of these side effects, gefitinib therapy was either interrupted for various durations of time or a dose reduction to 250 mg/day was made. After the introduction of these measures, a decline in side effects was observed in all patients, and treatment could be continued in

### Table 1. Baseline characteristics of patients with HNSCC treated with gefitinib

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis, years</td>
<td>61.5</td>
</tr>
<tr>
<td>Sex</td>
<td>47–78</td>
</tr>
<tr>
<td>Tumor, node, metastasis classification at diagnosis</td>
<td></td>
</tr>
<tr>
<td>T2N0M0</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>T2N2bM0</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>T3N2bM0</td>
<td>2/8 (25)</td>
</tr>
<tr>
<td>T3N2cM1</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>T4N2M1</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>T4N0M0</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>No information</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>6/8 (75)</td>
</tr>
<tr>
<td>No</td>
<td>2/8 (25)</td>
</tr>
<tr>
<td>Alcohol</td>
<td>4/8 (50)</td>
</tr>
<tr>
<td>No</td>
<td>4/8 (50)</td>
</tr>
<tr>
<td>Pretreatment (before gefitinib)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>Surgery (a)</td>
<td>0/8 (0)</td>
</tr>
<tr>
<td>Neck dissection (b)</td>
<td>0/8 (0)</td>
</tr>
<tr>
<td>Radiotherapy (c)</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>Chemotherapy (d)</td>
<td>0/8 (0)</td>
</tr>
<tr>
<td>a + b + c</td>
<td>1/8 (12.5)</td>
</tr>
<tr>
<td>a + b + c + d</td>
<td>4/8 (50)</td>
</tr>
<tr>
<td>c + d</td>
<td>1/8 (12.5)</td>
</tr>
</tbody>
</table>
Discussion

In non-squamous-cell lung cancer, mutations in the EGFR gene occur at a relatively high frequency [24], but we have not found any mutations in the EGFR in our HNSCC patients. Today, in lung cancer, EGFR mutations are accepted as predictive markers of the benefit of gefitinib therapy [25, 26]. There is a significant superiority of gefitinib in patients bearing tumors with an EGFR mutation and an inferiority of gefitinib to conventional chemotherapy in non-mutated cancers. For HNSCC, we cannot confirm this result previously derived from lung cancer. In our pilot study, we did not find any relevant mutations in the EGFR although we observed a response rate of 37.5%. The absence of EGFR mutations is consistent with the data of Loeffler-Ragget al. [27] who observed only 1 mutation in 100 cases of HNSCC. Additionally, a Spanish study (31 patients), a study from Japan [28] and a study from Minneapolis (20 patients) did not identify any mutations in HNSCC [29].

Similarly to our trial, the phase II study by Cohen et al. [19] demonstrated an objective response rate of 11% in patients with recurrent and metastatic HNSCC who were treated with 500 mg/day of gefitinib. In the study by Kirby et al. [30], it was observed that gefitinib was well tolerated and resulted in symptomatic improvement in one-third of the patients.

Similarly, the average PFS of 6.25 (minimum 1.3/maximum 10.8) months in our trial is in agreement with the previous studies. The median PFS and OS were 1.8 and 5.5 months, respectively, in the study by Cohen et al. [31] with 250 mg/day of gefitinib, whereas they were 3.4 and 8.1 months, respectively, with 500 mg/day of gefitinib [19]. With an OS of 7.4 (minimum 4.1/maximum 10.8) months, our results are in the same range. The quality of life of the patients improved temporarily during the first weeks of therapy. In our study, 50% of the patients (4 of 8) had a PFS of longer than 200 days, and the average PFS was 180 days in all patients analyzed.

Besides the retrospective study of Murray et al. [32] who analyzed 19 tumor specimens from patients treated with gefitinib, our trial is the only one to analyze the EGFR mutation status in a cohort of patients treated with gefitinib. Thus, even without a mutation in the EGFR, there is an objective response to gefitinib in HNSCC. There are, of course, some limitations to the interpretations being derived from this study, due to the small number of patients analyzed. While we cannot exclude that some rare patients with an EGFR mutation would benefit even more from gefitinib, we demonstrated

Results of Gefitinib Therapy

The tumor response evaluation was carried out according to the RECIST criteria. 3 patients had a partial response (PR), 4 patients had SD, and 1 patient had progressive disease (PD) (fig. 1). The median PFS was 6.25 months (range 1.3–10.8 months). The median OS was 7.4 months (range 4.1–10.8 months). The 3 patients without prior systemic therapy had a PFS of 2.6, 5.8, and 10.8 months, respectively, which is in the same range as for the patients previously treated with chemotherapy.

Results of the EGF Receptor Mutation Analysis

In 6 of 8 patients, an EGFR mutation analysis could be performed (75%). 5 patients had no mutation in the sequenced part of exons 19–21, and 1 patient had a silent guanine-to-adenosine mutation in position 2607. In the other 2 patients, no sequence was obtained (table 2). The 2 tumors from which a sequence could not be obtained showed either SD or PD in response to therapy with gefitinib. Thus, the responses to gefitinib were independent of the EGFR mutation status.

Fig. 1. Response of HNSCC to gefitinib. Changes from baseline in radiographic measurements (RECIST) at the time of maximum response in patients treated with gefitinib. The mean change was –8.4% (standard deviation, 30%).
that there are objective responses in the absence of mutations in exons 19–21 of the EGFR. However, these results exclude the EGFR mutation status to predict the observed responses. Whether it would be a marker of even better responses than the ones observed in the very rare mutated tumors cannot be determined from our small pilot trial without any such case. Multiple predictive markers for the sensitivity or resistance to gefitinib in HNSCC have been investigated either in tumor cell lines or in cancer specimens. Amplification of the EGFR has been implied as a prognostic marker in HNSCC [33]. However, other EGFR/ErbB receptor family members may contribute to resistance to gefitinib [34]. In a genomic analysis, tumor cell line markers associated with epithelial-mesenchymal transition have been associated with resistance to gefitinib [35]. A proteomic analysis correlated gefitinib sensitivity with p-AKT and p-STAT3 activation in HNSCC cell lines and tumor specimens, which implies that p-AKT and p-STAT3 could serve as potentially useful biomarkers and drug targets [36]. Wheeler et al. [37] analyzed c-myc and cyclin D1 as predictors for gefitinib therapy. 10 paired tumor samples were tested by RT-PCR for c-myc and cyclin D1 gene expression. No correlation was found between changes in the expression of these genes and the clinical benefit of gefitinib. EGFRvIII has been proposed as a marker of resistance to therapy with cetuximab [38]; its role as a predictive marker for gefitinib is currently unknown. In summary, there is currently no reliable predictive marker identified for gefitinib therapy in HNSCC, and the establishment of such a marker is still a clinical need.

Conclusion

In HNSCC, EGFR mutation analysis seems not to be helpful in the prediction of benefit from gefitinib. Thus, there is still a need to identify other factors influencing the response to gefitinib.

Acknowledgements

We thank the patients and their families who participated in the study. This work was supported by the Krebsliga beider Basel and a pilot grant from the Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung (SAKK).

Disclosure Statement

The authors declare that there are no conflicts of interest with respect to this study.

References


